Stockreport

Molecular Partners Reports Highlights and Financial Results for Full Year 2025

Molecular Partners AG - American Depositary Shares  (MOLN) 
PDF Initiated US Phase 1/2a study of DLL3-targeting 212Pb-based Radio-DARPin candidate MP0712 for SCLC and other neuroendocrine cancers, co-developed with strategic partner [Read more]